Muhammed Sönmez

Dr. Muhammed Sönmez


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2026 in Life
Verified
Journal Article
Open access
PDF file
MDMehmet Ali Durmuş
Mehmet Ali Durmuş
ÖTÖMER FARUK TOPALOĞLU
ÖMER FARUK TOPALOĞLU
MSMuhammed Sönmez
Muhammed Sönmez
STSinan Taşdogan
Sinan Taşdogan
SDSalih Demir
Salih Demir
HTHūseyin Saygin Tuna
Hūseyin Saygin Tuna
Selective arterial embolization (SAE) is an established nephron-sparing option for renal angiomyolipoma (AML), but it remains unclear whether giant lesions (≥10 cm) respond less well or carry higher procedural risk. We retrospectively reviewed 40 patients treated with SAE between 2020 and 2025. Tris-acryl gelatin microspheres (300–500 µm) were the primary embolic agent; N-butyl cyanoacrylate or microcoils were added in 12 patients with acute bleeding or large aneurysms. Pre- and post-procedural values were compared with the Wilcoxon signed-rank test, and giant and non-giant lesions with the Mann–Whitney U and Fisher’s exact tests. Thirty-six patients (90%) were women, and 14 (35%) had giant lesions. Technical success reached 100% and clinical success 97.5% (39/40); no major complications occurred. Mean tumor diameter decreased by 13.6% (83.6 ± 47.2 vs. 72.7 ± 41.8 mm; p < 0.001), while estimated glomerular filtration rate (eGFR) did not change significantly (94.6 ± 21.6 vs. 87.7 ± 33.1 mL/min/1.73 m2; p = 0.203). Giant and non-giant lesions did not differ significantly in clinical success (92.9% vs. 100%; p > 0.999), shrinkage, or renal function (all p > 0.05). One patient with a giant, multifocal, tuberous sclerosis complex-associated lesion did not respond and underwent nephrectomy. These data suggest that tumor size alone may not preclude SAE.